Kelun Biotech partner reports positive asthma Phase 2 trial results
Windward Bio reported positive interim Phase 2 POLARIS 1 trial results for asthma drug candidate SKB378 WIN378 and initiated a global Phase 3 study alongside partner Kelun Biotech
An investigational EGFR x HER3 antibody-drug conjugate showed promising results in a phase III trial for lung cancer patients. The therapy demonstrated a tolerable safety profile and increased clinical activity at the recommended dose of 2.5 mg/kg. The trial found a 33.3% objective response rate, 29.6% confirmed response rate, and a median progression-free survival of 6.9 months. These results support the advancement of the therapy into global Phase III evaluation.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
